Show simple item record

dc.contributor.authorHelland, Åslaug
dc.contributor.authorRussnes, Hege Elisabeth Giercksky
dc.contributor.authorFagereng, Gro Live
dc.contributor.authorAl-Shibli, Khalid Ibrahim
dc.contributor.authorAndersson, Yvonne
dc.contributor.authorBerg, Thomas
dc.contributor.authorBjørge, Line
dc.contributor.authorBlix, Egil Støre
dc.contributor.authorBjerkehagen, Bodil
dc.contributor.authorBrabrand, Sigmund
dc.contributor.authorCAMERON, MARTE
dc.contributor.authorDalhaug, Astrid
dc.contributor.authorDietzel, Dalia
dc.contributor.authorDønnem, Tom
dc.contributor.authorEnerly, Espen
dc.contributor.authorFlobak, Åsmund
dc.contributor.authorFluge, Sverre
dc.contributor.authorGilje, Bjørnar
dc.contributor.authorGjertsen, Bjørn Tore
dc.contributor.authorGrønberg, Bjørn Henning
dc.contributor.authorGrønås, Kari
dc.contributor.authorGuren, Tormod Kyrre
dc.contributor.authorHamre, Hanne Mari
dc.contributor.authorHaug, Åse
dc.contributor.authorHeinrich, Daniel
dc.contributor.authorHjortland, Geir Olav
dc.contributor.authorHovig, Eivind
dc.contributor.authorHovland, Randi
dc.contributor.authorIversen, Ann-Charlotte
dc.contributor.authorJanssen, Emiel
dc.contributor.authorKyte, Jon A
dc.contributor.authorGythfeldt, Hedda
dc.contributor.authorLothe, Ragnhild Adelheid
dc.contributor.authorLund, Jo-Åsmund
dc.contributor.authorMeza, Leonardo Zepeda
dc.contributor.authorMunthe-Kaas, Monica Cheng
dc.contributor.authorNguyen, Olav Toai Duc
dc.contributor.authorNiehusmann, Pitt
dc.contributor.authorNilsen, Hilde
dc.contributor.authorPuco, Katarina
dc.contributor.authorRee, Anne Hansen
dc.contributor.authorRiste, Tonje Bøyum
dc.contributor.authorSemb, Karin
dc.contributor.authorSteinskog, Eli Sihn Samdal
dc.contributor.authorStensvold, Andreas
dc.contributor.authorSuhrke, Pål
dc.contributor.authorTennøe, Øyvind Krohn
dc.contributor.authorTjønnfjord, Geir Erland
dc.contributor.authorVassbotn, Liv Jorunn
dc.contributor.authorAas, Eline
dc.contributor.authorAasebø, Kristine Øverås
dc.contributor.authorTasken, Kjetil
dc.contributor.authorSmeland, Sigbjørn
dc.identifier.citationHelland, Å., Russnes, H. G., Fagereng, G. L., Al-Shibli, K., Andersson, Y., Berg, T., ... & Smeland, S. (2022). Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of translational medicine, 20(1), 1-11.en_US
dc.description.abstractBackground Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer specific pathways have been developed and approved for subgroups of patients. These drugs might just as well be efficient in other diagnostic subgroups, not investigated in pharma-led clinical studies, but their potential use on new indications is never explored due to limited number of patients. Methods In this national, investigator-initiated, prospective, open-label, non-randomized combined basket- and umbrella-trial, patients are enrolled in multiple parallel cohorts. Each cohort is defined by the patient’s tumour type, molecular profile of the tumour, and study drug. Treatment outcome in each cohort is monitored by using a Simon two-stage-like ‘admissible’ monitoring plan to identify evidence of clinical activity. All drugs available in IMPRESS-Norway have regulatory approval and are funded by pharmaceutical companies. Molecular diagnostics are funded by the public health care system. Discussion Precision oncology means to stratify treatment based on specific patient characteristics and the molecular profile of the tumor. Use of targeted drugs is currently restricted to specific biomarker-defined subgroups of patients according to their market authorization. However, other cancer patients might also benefit of treatment with these drugs if the same biomarker is present. The emerging technologies in molecular diagnostics are now being implemented in Norway and it is publicly reimbursed, thus more cancer patients will have a more comprehensive genomic profiling of their tumour. Patients with actionable genomic alterations in their tumour may have the possibility to try precision cancer drugs through IMPRESS-Norway, if standard treatment is no longer an option, and the drugs are available in the study. This might benefit some patients. In addition, it is a good example of a public–private collaboration to establish a national infrastructure for precision oncology.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleImproving public cancer care by implementing precision medicine in Norway: IMPRESS-Norwayen_US
dc.title.alternativeImproving public cancer care by implementing precision medicine in Norway: IMPRESS-Norwayen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.rights.holderThe authorsen_US
dc.subject.nsiVDP::Medisinske Fag: 700en_US
dc.source.journalJournal of Translational Medicineen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal